Benitec Biopharm SEC Filings

Benitec Biopharma Inc. is registering and selling 7,411,481 shares of common stock at $13.50 per share. The deal combines a firm-commitment underwritten offering of 5,930,000 shares and a concurrent registered direct sale of 1,481,481 shares, both priced identically. The company has granted underwriters a 30‑day option to purchase up to 889,500 additional shares.

Gross proceeds reflect the pricing: the tables show proceeds to the company of $94,051,694 before expenses, and the company estimates net proceeds of approximately $93.6 million, or $104.9 million if the option is fully exercised. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Shares outstanding were 26,250,469 as of June 30, 2025.

Benitec plans to use the net proceeds, together with existing cash, to fund continued development of its product candidate programs, working capital, and other general corporate purposes. The underwritten public offering and the concurrent registered direct offering are contingent on each other closing. The offering price represents a discount to the last reported price of $15.78 on November 5, 2025, and new investors will incur immediate dilution described in the filing.

Benitec Biopharma Inc. (BNTC) launched a mixed primary financing, comprising an underwritten offering of common stock and pre-funded warrants, alongside a concurrent registered direct offering of common stock. The prospectus also registers the shares issuable upon exercise of the pre-funded warrants. Pre-funded warrants are immediately exercisable for one share each at a $0.0001 exercise price, with beneficial ownership limits of 4.99% (or, at the holder’s election, 9.99% or up to 19.99%).

The company’s common stock last traded at $15.71 on November 4, 2025. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Net proceeds are intended to fund continued development of product candidates, working capital and general corporate purposes. The underwritten deal includes a 30‑day option to purchase additional shares. A concurrent registered direct offering is being made to Averill entities, affiliates of Suvretta, which beneficially own approximately 49.9% of the company.

Benitec Biopharma Inc. appointed Dr. Sharon Mates to its Board. She joins as a Class I director effective November 3, 2025, with a term through the 2026 annual meeting. The Board deemed her independent under Nasdaq rules. In connection with the appointment, she will receive stock options valued at $450,000, with the number of shares determined by dividing $450,000 by the Common Stock closing price on November 5, 2025. These options vest in full on the earlier of immediately prior to the 2026 annual meeting or the first anniversary of the grant date.

The FDA granted Fast Track Designation to BB-301 for OPMD. The company also announced a live webcast of its latest interim clinical data presentation at 8:00 a.m. Eastern on November 3, 2025. Related press releases and presentation materials were included as exhibits.

Benitec Biopharma Inc. appointed Dr. Sharon Mates to its Board. She joins as a Class I director effective November 3, 2025, with a term through the 2026 annual meeting. The Board deemed her independent under Nasdaq rules. In connection with the appointment, she will receive stock options valued at $450,000, with the number of shares determined by dividing $450,000 by the Common Stock closing price on November 5, 2025. These options vest in full on the earlier of immediately prior to the 2026 annual meeting or the first anniversary of the grant date.

The FDA granted Fast Track Designation to BB-301 for OPMD. The company also announced a live webcast of its latest interim clinical data presentation at 8:00 a.m. Eastern on November 3, 2025. Related press releases and presentation materials were included as exhibits.

Benitec Biopharma Inc. (BNTC) will hold its 2025 Annual Meeting virtually on December 1, 2025 at 1:00 p.m. PT. Stockholders of record at the close of business on October 10, 2025 may vote. As of the record date, 26,250,469 shares of common stock were outstanding. Holders will vote on three items: (1) elect two Class III directors (Dr. Jerel Banks and Megan Boston), (2) ratify Baker Tilly US, LLP as auditor for fiscal year ending June 30, 2026, and (3) approve a non-binding say‑on‑pay advisory vote.

The company will conduct the meeting at www.meetnow.global/M4KC5WC, with voting also available via www.investorvote.com/BNTC. The outstanding count excludes unexercised pre‑funded warrants for up to 15,270,806 shares, which carry no voting rights until exercised. The proxy details quorum and vote standards, committee composition, and director independence. Principal holders include entities affiliated with Suvretta Capital at 49.9%. The proxy also discloses a March 2025 financing with gross proceeds of $30.5 million and net proceeds of $28.2 million, and reports auditor fees of $666,290 for fiscal 2025.

Benitec Biopharma Inc. (BNTC) has filed a Form S-3 shelf registration to enable sales of common stock, debt securities, warrants and units. The prospectus references a February 2024 S-3 Shelf and a November 2024 S-3 Shelf; as of the filing, $94,541,030 of securities registered under the November 2024 S-3 Shelf remain unsold and are included in this new registration statement. The company describes BB-301, an AAV-based gene therapy using a "silence and replace" approach for OPMD, and notes that BB-301 has Orphan Drug Designation in the U.S. and EU. The prospectus incorporates by reference the companys Form 10-K for the year ended June 30, 2025, and warns investors to review the risk factors disclosed in that Annual Report and subsequent SEC filings.

Benitec Biopharma Inc. (BNTC) has filed a Form S-3 shelf registration to enable sales of common stock, debt securities, warrants and units. The prospectus references a February 2024 S-3 Shelf and a November 2024 S-3 Shelf; as of the filing, $94,541,030 of securities registered under the November 2024 S-3 Shelf remain unsold and are included in this new registration statement. The company describes BB-301, an AAV-based gene therapy using a "silence and replace" approach for OPMD, and notes that BB-301 has Orphan Drug Designation in the U.S. and EU. The prospectus incorporates by reference the companys Form 10-K for the year ended June 30, 2025, and warns investors to review the risk factors disclosed in that Annual Report and subsequent SEC filings.

Benitec Biopharma Inc. furnished an update on its business by issuing a press release with financial results for its full year ended June 30, 2025 and an operational update. The company attached this press release as Exhibit 99.1 to the current report and specified that this information is being furnished under the results of operations and financial condition item, rather than treated as filed for liability purposes or automatically incorporated into other documents.

Benitec Biopharma Inc. furnished an update on its business by issuing a press release with financial results for its full year ended June 30, 2025 and an operational update. The company attached this press release as Exhibit 99.1 to the current report and specified that this information is being furnished under the results of operations and financial condition item, rather than treated as filed for liability purposes or automatically incorporated into other documents.

Benitec Biopharma Inc. (BNTC) is an early-stage genetic medicines company developing BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has received Orphan Drug Designation in the United States and the European Union and is in a Phase 1b/2a single-arm, open-label, sequential dose-escalation study (NCT06185673) with dosing delivered directly to pharyngeal muscles and interim safety/efficacy readouts expected at 180-day intervals.

Financially, the company reported $97.7 million in cash and cash equivalents as of June 30, 2025, used cash in operations of $23.6 million for the year, and raised material proceeds during the year (including a $40.0 million PIPE and additional offerings), with total net proceeds from issuances and warrant exercises during the fiscal year stated at $70.5 million. The company disclosed a restatement related to prior-period recognition of certain non-cash share-based compensation expenses and notes it will continue to incur operating losses and depend on financing to fund operations.

Benitec Biopharma Inc. (BNTC) is an early-stage genetic medicines company developing BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has received Orphan Drug Designation in the United States and the European Union and is in a Phase 1b/2a single-arm, open-label, sequential dose-escalation study (NCT06185673) with dosing delivered directly to pharyngeal muscles and interim safety/efficacy readouts expected at 180-day intervals.

Financially, the company reported $97.7 million in cash and cash equivalents as of June 30, 2025, used cash in operations of $23.6 million for the year, and raised material proceeds during the year (including a $40.0 million PIPE and additional offerings), with total net proceeds from issuances and warrant exercises during the fiscal year stated at $70.5 million. The company disclosed a restatement related to prior-period recognition of certain non-cash share-based compensation expenses and notes it will continue to incur operating losses and depend on financing to fund operations.

Janus Henderson Group plc and its affiliate Janus Henderson Biotech Innovation Master Fund Ltd report beneficial ownership stakes in Benitec Biopharma Inc. Janus Henderson Group is reported to beneficially own 2,902,794 shares, equal to 11.3% of the common stock, with shared voting and shared dispositive power over those shares. The Biotech Innovation Master Fund is reported to beneficially own 2,193,481 shares, equal to 8.6% of the common stock, also held with shared voting and dispositive power.

The filing includes an explicit certification that the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The filing identifies the reporting persons as an investment adviser/holding company and an investment vehicle.

Janus Henderson Group plc and an affiliated fund report beneficial holdings in Benitec Biopharma Inc. common stock (CUSIP 08205P209). The filing shows Janus Henderson Group plc with 25,600,210 shares of shared voting and dispositive power, representing 11.3% of the class. An affiliated vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports 2,193,481 shares (shared voting and dispositive power), representing 8.6%. The schedule includes a certification that the securities were acquired in the ordinary course of business and a power of attorney executed by Janus Henderson Group plc authorizing named attorneys-in-fact to file required ownership reports.